Welcome to the latest edition of the  BioLines Weekender

After a valiant fight, sadly, former BioNJ Chairman, Patient advocate, beloved industry member and friend Michael Becker passed away late last week. In December 2015, Michael was diagnosed with advanced (Stage IV) oropharyngeal cancer. An extraordinary man, Michael devoted his time during his cancer battle to educate about and advocate for HPV vaccination. He shared his story of adversity and daily triumph in his book, "A Walk with Purpose," which chronicles his journey from biotech CEO to Patient.
Michael was an iconic leader, a passionate advocate, a warm and wonderful human being and a dear friend. This is an enormous loss for us all. During his time as BioNJ Chairman, Michael made significant contributions to our organization -- making a difference at every turn. He will be sorely missed.
We had the pleasure last night of hosting our annual BioCruise with our good friends at NewYorkBIO. Thank you to everyone who joined us for a fun evening on the Hudson -- relaxing, networking and enjoying great food and music.

Please mark your calendars and save the dates for BioNJ's upcoming events this fall, including BioNJ's Manufacturing Briefing: Cell and Gene Therapy Manufacturing "Cracking the Code" on September 20, Patient Advocacy Summit: Educate, Engage and Empower on October 4 and C-Suite Summit: A New Horizon for Biopharma Innovation: Emerging Science, Access and Patient-Centricity on November 8. Visit www.BioNJ.org for details.

Because Patients Can't Wait®,
The BioNJ Team
BioNJ Calendar

Manufacturing Briefing
New Jersey Innovation Institute, Newark, NJ
Register today!
September 20, 2019
Patient Advocacy Summit 
Celgene, Summit, NJ
October 4, 2019
C-Suite Summit
Bridgewater Marriott, Bridgewater, NJ
November 8, 2019
Putting Patients First: The Value of Medical Innovation

Medical innovation enables longer and better quality lives and, in turn, reduces the costs of health care. Share with our community how your medical innovation is improving lives and impacting health care costs. Send us your Patient and related stories to [email protected]. Plus, click here for valuable tools and resources on the Value of Medical Innovation.

Princeton-based Sandoz Inc., a Novartis division, announced the U.S. retail launch of SYMJEPI™ (epinephrine) 0.3 mg and 0.15 mg Injections, making both the adult and pediatric doses immediately available in local pharmacies across the nation. SYMJEPI is a small, single-dose, pre-filled syringe and device combination as an alternative to epinephrine auto-injectors for the emergency treatment of allergic reactions (Type 1), including anaphylaxis, a severe reaction that can lead to death if left untreated. The U.S. Food and Drug Administration (FDA) recently highlighted ongoing shortages of epinephrine auto-injectors from several drug manufacturers, which can put people's lives in jeopardy if they have a severe allergic reaction and do not have access to this life-saving medicine.

BioNJ in the News

Featured in ROI-NJ
It's no secret that New Jersey, despite growing competition from other states, remains a stronghold for the pharmaceutical industry.  Which is why the ongoing political pressure nationally over the cost of drugs is relevant to, and tied to, the State's economy.  In recent years, drug manufacturers have focused on changing their messaging, highlighting the value to a person's life that their products bring.  A recent white paper from BioNJ highlights this value proposition, and its authors said changing the way pharmaceutical companies think of their products is as important. "Many more innovative medicines are in the pipeline," the white paper said.

Showing Our NJ Pride

BioNJ Member  SCYNEXIS , Inc. is an innovative biotech firm that develops promising anti-infective drugs. In 2015, when the company decided to relocate its headquarters from Durham, North Carolina, close proximity to New York City and financial institutions made Hudson County an attractive option. For the company and its employees, the county met SCYNEXIS ' needs for a well-educated employee pool, ample and diverse housing choices, extensive retail, dining, hospitality and recreational/entertainment amenities, and convenient access to public transportation and international airports. SCYNEXIS selected Jersey City as its new home and leased the entire 13th floor of the Class A 1 Evertrust Plaza building.

NJ Company News

Ever proud of our ecosystem, we are pleased to share our New Jersey Company News. Be sure to click on the article titles below to read the full release.

Ramsey-based BioNJ Member ADMA Biologics, Inc. announces the United States Food and Drug Administration has notified ADMA the licenses for BIVIGAM® and Nabi-HB® have been revoked from Biotest Pharmaceuticals Corporation, ("BPC") U.S. License No. 1792 and transferred and issued to ADMA's U.S. License No. 2019. "We are very pleased to announce the U.S. License transfer of BIVIGAM® and Nabi-HB® from BPC to ADMA, as this was the final remaining regulatory item from the acquisition of the Biotest Therapy Business Unit transaction," stated President and Chief Executive Officer, Adam Grossman.

Parsippany-based BioNJ Member Teva Pharmaceutical Industries Ltd. announced that the U.S. Food and Drug Administration (FDA) has approved AirDuo® Digihaler™ (fluticasone propionate 113 mcg and salmeterol 14 mcg) Inhalation Powder, a combination therapy digital inhaler with built-in sensors that connects to a companion mobile application to provide information on inhaler use to people with asthma. AirDuo® Digihaler™ is indicated for the treatment of asthma in patients aged 12 years and older. AirDuo® Digihaler is not used to relieve sudden breathing problems and won't replace a rescue inhaler.

Cranbury-based BioNJ Member Rafael Pharmaceuticals, Inc. announced the expansion of its Phase 3 clinical trial for patients with metastatic pancreatic cancer (AVENGER 500) into Israel. The multicenter, open-label, randomized pivotal trial is evaluating the efficacy and safety of Rafael's lead compound CPI-613®️ (devimistat) in combination with modified FOLFIRINOX (mFFX) as first-line therapy in patients with metastatic adenocarcinoma of the pancreas. The global study, currently in multiple U.S. sites, will now open in eight sites throughout Israel.

Summit-based BioNJ Member Engage Therapeutics, Inc. announced that data from a Phase 2a study of Staccato® alprazolam to suppress seizures in patients with epilepsy were published in the peer-review journal Epilepsia. This proof-of-concept study demonstrated that Staccato alprazolam delivered the drug deep into the lung and rapidly suppressed seizure or epileptiform activity in five photosensitive patients with epilepsy. This proof-of-concept study demonstrated that Staccato alprazolam delivered the drug deep into the lung and rapidly suppressed seizure or epileptiform activity in five photosensitive patients with epilepsy.

Princeton-based BioNJ Member Advaxis, Inc. announced new immune data from its ongoing ADXS-NEO Phase 1 clinical trial that further support the clinical potential for the company's platform in neoantigen-directed immunotherapies. ADXS-NEO is a personalized immunotherapy that is designed to help a patient's immune system recognize and respond to mutation-derived tumor antigens, or neoantigens, that are unique to his or her tumor. ADXS-NEO is designed to express tLLO fused to up to 40 patient-specific neoantigens arranged sequentially as beads-on-a-string.

Princeton-based BioNJ Member Genmab A/S announced that topline data from the Phase II GRIFFIN (MMY2004) study of newly diagnosed patients with multiple myeloma eligible for high-dose chemotherapy and autologous stem cell transplantation (ASCT), who were treated with daratumumab in combination with lenalidomide, bortezomib and dexamethasone (VRd), met its primary endpoint, demonstrating a higher percentage of stringent complete responses (sCR) than patients who received VRd alone. 

Princeton-based BioNJ Member Genmab A/S announced that its licensing partner, Janssen Biotech, Inc., has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (U.S. FDA) for the use of the subcutaneous (SubQ) formulation of daratumumab in multiple myeloma indications where the intravenous formulation of daratumumab is currently approved. In August 2012, Genmab granted Janssen an exclusive worldwide license to develop, manufacture and commercialize daratumumab. 

Raritan-based BioNJ Member The Janssen Pharmaceutical Companies of Johnson & Johnson announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking approval of a new subcutaneous (SC) formulation of DARZALEX® (daratumumab), an intravenous (IV) treatment approved for certain patients with multiple myeloma.

Raritan-based BioNJ Member The Janssen Pharmaceutical Companies of Johnson & Johnson announced new results from the Phase 3 EINSTEIN-Jr study, showing pediatric patients (aged birth to 17 years) treated with XARELTO® (rivaroxaban) had a similar low risk of recurrent venous thromboembolism (VTE) -- or blood clots -- and similar rates of bleeding when compared to current standard anticoagulation therapy. These results from the largest pediatric study ever conducted for the treatment of VTE also show that the efficacy and safety profile of XARELTO® in a pediatric population with VTE is comparable to what has been observed in previous studies of adults with VTE. 

Bridgewater-based BioNJ Member Allergan plc announced that the U.S. Food and Drug Administration ( FDA ) has accepted the company's New Drug Application (NDA) for Bimatoprost Sustained-Release (SR). Bimatoprost SR if approved would be the first-in-class sustained-release, biodegradable implant for the reduction of intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension. The FDA is expected to take action on the NDA by the end of the first half of 2020.

The U.S. Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for Bridgewater-based BioNJ Member Sanofi's isatuximab for the treatment of patients with relapsed/refractory multiple myeloma (RRMM). The target action date for the FDA decision is April 30, 2020. Isatuximab is an investigational monoclonal antibody that targets a specific epitope on the CD38 receptor of a plasma cell. The BLA is based on positive results from ICARIA-MM, an open-label pivotal Phase 3 clinical trial of isatuximab in patients with RRMM. 

BioNJ Member  Jazz Pharmaceuticals plc, with offices in  Ewing,  announced that the company has signed a definitive agreement under which Jazz has acquired  Redx Pharma's  (Redx) pan-RAF inhibitor program for the potential treatment of RAF and RAS mutant tumors.  Redx will perform certain pre-clinical activities for the program under a separate collaboration agreement with Jazz. Jazz will be responsible for further development, regulatory activities and commercialization.

Kenilworth-based BioNJ Member Merck & Co. announced that the U.S. Food and Drug Administration (FDA) has approved RECARBRIO™ (imipenem, cilastatin and relebactam) for injection, 1.25 grams, a new combination antibacterial. RECARBRIO is indicated in patients 18 years of age and older who have limited or no alternative treatment options, for the treatment of complicated urinary tract infections (cUTI), including pyelonephritis, caused by the following susceptible Gram-negative microorganisms: Enterobacter cloacae, Escherichia coli, Klebsiella aerogenes, Klebsiella pneumoniae and Pseudomonas aeruginosa

Kenilworth-based BioNJ Member Merck & Co. announced that the U.S. Food and Drug Administration (FDA) has accepted for review six supplemental Biologics License Applications (sBLAs) to update the dosing frequency for KEYTRUDA, Merck's anti-PD-1 therapy, to include an every-six-weeks (Q6W) dosing schedule option. Merck is seeking FDA approval of a 400 mg Q6W dose infused over 30 minutes for KEYTRUDA indications in melanoma, classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, gastric cancer, hepatocellular carcinoma and Merkel cell carcinoma.

Basking Ridge-based BioNJ Member Ipsen and Servier announced preliminary data from the Phase 1/2 study of the investigational use of liposomal irinotecan (ONIVYDE®) in combination with 5- fluorouracil/leucovorin (5-FU/LV) and oxaliplatin (OX) in study patients with previously untreated metastatic pancreatic ductal adenocarcinoma cancer (PDAC) at the ESMO 21st World Congress on Gastrointestinal Cancer in Barcelona. The results included preliminary safety and efficacy data from an ongoing multicenter, open-label, dose-escalation study, which aims to determine the maximum tolerated dose and the recommended dose to be used in future clinical studies.

Princeton-based BioNJ Member Evotec SE announced that the company has acquired assets from the stem cell specialist Ncardia AG to advance Evotec's iPSC platform, one of the leading iPSC-based discovery platforms in the industry. The acquired assets include intellectual property relevant for iPSC-based phenotypic drug discovery, an existing cellular product business around iPSC-derived cells, as well as 17 strong team of stem cell biology experts operating from laboratories at the BioCampus Cologne.

Princeton-based BioNJ Member Evotec SE announced the formation of Breakpoint Therapeutics GmbH, a spin-off company focusing on the development of Evotec's DNA damage response ("DDR") portfolio, comprising discovery-stage assets and drug targets that promise broad therapeutic application in a variety of cancers. Breakpoint Therapeutics' mission is to develop first and best-in-class oncology drugs that interfere with DNA repair and replication stress pathways to facilitate the cure of therapy-resistant cancers.

Rutherford-based BioNJ Member  Cancer Genetics Inc.  announced the sale of its biopharma business to Parsippany-based  Interpace Diagnostics Group Inc.  for $23.5 million.  Cancer Genetics said it sold the business unit under its junior secured lender,  Partners for Growth IV L.P. The company also announced the $1 million sale of an asset used in its clinical laboratory business to  siParadigm LLC , a Pine Brook-based specialty reference laboratory focused on hematopathology and oncology diagnostics.

Princeton-based BioNJ Member Bristol-Myers Squibb Company, Whippany-based Bayer and Ono Pharmaceutical Co., Ltd. announced the three companies have entered into a clinical collaboration agreement to evaluate the combination of Bayer's kinase inhibitor Stivarga ®  (regorafenib) and Bristol-Myers Squibb's / Ono's anti-PD-1 immune checkpoint inhibitor, Opdivo ®  (nivolumab) in patients with micro-satellite stable metastatic colorectal cancer (MSS mCRC), the most common form of mCRC.

Whippany-based  Bayer announced the U.S. Food and Drug Administration (FDA) has approved Gadavist ®  (gadobutrol) injection for use in cardiac magnetic resonance (MR) imaging to assess myocardial perfusion (stress, rest) and late gadolinium enhancement in adult patients with known or suspected coronary artery disease (CAD). Gadavist is now the first and only contrast agent FDA approved for use in cardiac MR -- an important diagnostic tool for patients with CAD.

Versant Ventures' Century Therapeutics has  exited stealth with $250 million to take allogeneic cell therapies into the clinic. Whippany -based Bayer's VC wing led the investment with the support of Versant and Fujifilm Cellular Dynamics (FCDI).  Century, like other allogeneic cell therapy players, is trying to improve on autologous products that require the administration of a patient's own cells back to them by creating off-the-shelf alternatives. 

Somerset-based Catalent Biologics announced a long-term strategic agreement for the development and manufacturing of Zolgensma® (onasemnogene abeparvovec-xioi), an AveXis gene therapy treatment for spinal muscular atrophy (SMA). SMA is a rare genetic disease that leads to progressive muscle weakness, paralysis, and when left untreated in its most severe form, permanent ventilation or death for most patients by age 2.

Adlai Nortye, which chose the New Jersey Economic Development Authority's New Jersey Bioscience Center - Step-Out Labs at North Brunswick as its national headquarters last year, has since experienced exponential growth, it said. The China-based biopharmaceutical company was one of the first tenants to move into the facility shortly after it opened in June 2018.  Since moving there last August, Adlai Nortye has grown from one employee to 18 workers in New Jersey.

Cranbury-based  Outlook Therapeutics, Inc. , a late clinical-stage biopharmaceutical company focused on developing ONS-5010, a proprietary ophthalmic bevacizumab product candidate for the treatment of wet age related macular degeneration (wet AMD) and other retina diseases, announced that it has dosed the first patient in the ONS-5010-002 Phase 3 clinical trial. ONS-5010-002 is the second of the Company's two required adequate and well controlled Phase 3 clinical trials evaluating ONS-5010 against ranibizumab (Lucentis®) for wet AMD. 

GlaxoSmithKline plc, with offices in Warren, announced positive results from PRIMA (ENGOT-OV26/GOG-3012), the Phase 3 randomized, double-blind, placebo-controlled, study of ZEJULA (niraparib) as a maintenance therapy in patients with first-line ovarian cancer following platinum-based chemotherapy. The study met its primary endpoint of a statistically significant improvement in progression free survival for women regardless of their biomarker status.

Boehringer Ingelheim, with offices in New Brunswick, announced its acquisition of all shares of AMAL Therapeutics SA, a private Swiss biotechnology company focused on cancer immunotherapy and advancing first-in-class therapeutic cancer vaccines derived from its technology platform KISIMA. AMAL's lead vaccine ATP128 is currently developed for stage IV colorectal cancer and is slated to begin first-in-human trials later this month. 

Bedminster-based  Mallinckrodt plc   and Silence Therapeutics plc  announce that, further to the collaboration recently announced,  Mallinckrodt , acting through a subsidiary company, has agreed to make an equity investment of $5 million in Silence Therapeutics Mallinckrodt is subscribing for a total of 5,062,167 new ordinary shares at an issue price of 79p per share, representing a 10 percent premium to Silence's 20-day, volume-weighted average price.  Application will be made to the London Stock Exchange for the admission of the 5,062,167 new ordinary shares to be subscribed for trading on AIM

Princeton -based SunGen Pharma announced it has received its sixth ANDA approval from the U.S. Food and Drug Administration (FDA). The sixth approved ANDA is for Methylprednisolone tablets, 4 mg. This drug product is a corticosteroid used to treat conditions including arthritis, allergic reactions and immune system disorders, as well as dermatologic, ophthalmic, respiratory and gastrointestinal diseases. Methylprednisolone tablets had total U.S. sales of $93 million for Q1 of 2019, and $113 million and $124 million, respectively, for 2018 and 2017 according to IQVIA.

Bedminster -based  Aerie Pharmaceuticals, Inc.  announced that enrollment for its Phase 2 clinical trial of netarsudil ophthalmic solution in  Japan  is complete, a milestone reached several months earlier than previously anticipated. The first patients to enter this prospective, double-masked, multi-center, placebo-controlled, parallel group Phase 2 study were dosed in late  March 2019 .

BeiGene, Ltd., with offices in Ridgefield Park, announced that the China National Medical Products Administration (NMPA, formerly known as the CFDA) has granted priority review status to the supplemental new drug application (sNDA) for tislelizumab, an investigational Fc-engineered anti-PD-1 antibody, for patients with previously treated locally-advanced or metastatic urothelial carcinoma (UC). 

Princeton-based Motif Bio plc  announced that it has submitted a meeting request and package to the  U.S. Food & Drug Administration  ( FDA ) related to the company's lead product candidate, iclaprim. In the minutes from a  May 3, 2019 , Type A meeting, the  FDA  indicated that an additional clinical trial will be required prior to granting marketing approval of iclaprim. The company has been encouraged by the  FDA  to put forth a proposal for such a study. 

Berkeley Heights-based Axtria has been named by the CIOReview magazine in their "20 Most Promising Data Analytics Solution Providers 2019" list. "We are proud to receive this prestigious recognition.Our modern, cloud-based platforms are transforming the product commercialization journey in the life sciences industry. With platforms that deploy AI/ML and embedded analytics, we help our customers complete the journey, from data-to-insights-to-operations at speed, maximizing sales while focusing on improving patient outcomes," says Jassi Chadha, Co-Founder and CEO of Axtria.

Princeton-based  Certara , announced  the entire staff from  Compass Strategic Consulting  (Compass) has joined the company's Evidence & Access group.  Certara enables superior drug development and patient care decision making through model-informed drug development, regulatory science, real-world evidence solutions and knowledge integration.
Certara Evidence & Access was formed through the acquisition of Analytica Laser, a market access, health economics and real-world evidence consultancy, and BaseCase, a life sciences value communications technology company. 

Princeton-based  Certara , announced it has formed a new practice area called Certara Global Health (CGH) to focus its technological expertise on helping to achieve equity in health for all people worldwide. CGH is a new product development innovation practice inspired by Certara's drug development and scientific due diligence work for the Bill & Melinda Gates Foundation. "Certara Global Health will bring together talent, technology, software, systems and processes to accelerate the development of medicines for those that need them most," said Craig Rayner, Senior Vice President and Co-Lead of CGH.

Glenmark Pharmaceuticals Ltd., with offices in  Mahwah, and Basking Ridge-based Torrent Pharmaceuticals Limited announced that they have entered into a non-exclusive sub-licensing agreement to co-market sodium glucose co-transporter-2 (SGLT2) inhibitor, Remogliflozin Etabonate (Remogliflozin) in India. Under the terms of the agreement, Glenmark will receive license fees and royalties for the non-exclusive sub-license rights from Torrent. Glenmark will manufacture and supply Remogliflozin while Torrent will market the drug under its own trademark 'Zucator' in India.

Funding News

The Innovation and Research Fellowship Program (IRFP) grant funds are provided to support technological research and the innovation ecosystem in New Jersey and to encourage Ph.D. candidates/graduates to continue their research in fellowship with New Jersey's science and technology companies.  The IRFP grant monies shall be used by the grantee employer primarily as salary to the fellow. Upon showing good cause by the applicant employer within the body of the IRFP grant application, the expenditure for equipment and/or conference attendance of an amount that is five percent of the total grant amount may be authorized at the discretion of the Commissioner. 

First Lady Tammy Murphy and the New Jersey Economic Development Authority announced that the NJEDA Board of Directors approved a proposal to organize a New Jersey chapter of  Golden Seeds , a national angel investor network dedicated to investing in women-led startup companies. The collaboration between First Lady Murphy's Office, the Economic Development Authority and Golden Seeds will advance Governor Phil Murphy's efforts to make New Jersey the "State of Innovation" by providing new funding sources and mentorship opportunities for female entrepreneurs.

Furthering his commitment to grow New Jersey's innovation economy by increasing access to funding for early-stage businesses, Governor Phil Murphy signed Assembly Bill 5604 on June 30, expanding New Jersey's Angel Investor Tax Credit Program. The program, which provides a tax credit for a percentage of an angel investor's investment in a qualifying emerging New Jersey technology or life science business, helps attract early-stage and growth capital for innovative New Jersey companies.

Biotechnology start-up  Big Magic Inc.  is now the second business taking advantage of the State's NJ Ignite program -- a rent subsidy State economic incentive for companies eyeing a move into one of the State's existing collaborative workspaces and incubators. Big Magic recently made a move into VentureLink, a 108,000-square-foot incubator at the NJIT campus in Newark which hosts more than 60 additional technology and life science companiesThe EDA's NJ Ignite program subsidizes part of the rent for start-ups moving into incubators or collaborative workspaces for periods of generally two, four or six months. 

People in the News

Michael Becker , former BioNJ Chairman and biotechnology industry investor and executive who spent his final years as an advocate for the human papillomavirus (HPV) virus vaccine, died Tuesday, July 9.  Mr.  Becker was diagnosed with late-stage head and neck cancer, caused by HPV, in December 2015. Earlier in his career, he spent time as CEO of two New Jersey biopharmaceutical companies, Cytogen and Vioquest Pharmaceuticals, focused on the treatment and diagnosis of cancer. While dealing with terminal cancer, Mr. Becker took time to write a book, A Walk with a Purpose: Memoir of a Bioentrepreneur.

There are a lot of places where lawyers can demonstrate their skills and acumen -- the courtroom, the boardroom, legislative chambers or at the bargaining table.  That range is on full display among the attorneys who made our Law Power 50 list. Congratulations to
these BioNJ Members:
  • Joseph Boccassini, McCarter & English
  • Kathleen Boozang, David Lopez and Kimberly Mutcherson,  Seton Hall, Rutgers-Newark and Rutgers-Camden 
  • Susan Feeney, McCarter & English
  • Ann Gavzy, Hackensack Meridian Health
  • Julia Lopez, Reed Smith
  • Audrey Murph, Hackensack Meridian Health
  • Dave Sorin, McCarter & English
  • Michael H. Ullmann, Johnson & Johnson
  • Gary Wingens, Lowenstein Sandler LLP
  • Jennifer Zachary, Merck & Co.  

Institution and Education News

Researchers at Rutgers University have created a device that can determine whether targeted chemotherapy drugs are working on individual cancer patients.  The portable device, which uses artificial intelligence and biosensors, is up to 95.9 percent accurate in counting live cancer cells when they pass through electrodes, according to a study published in the journal  Microsystems & Nanoengineering .

More than $2 million in grants recently awarded to Rutgers Cancer Institute of New Jersey resident researcher  Daniel Herranz Benito, Ph.D. , will support examination of potential treatment targets for a rare and aggressive blood cancer. T-cell acute lymphoblastic leukemia (T-ALL) is a type of ALL that impacts both children and adults. Most forms of ALL stem from early development of B-cells in the immune system. T-ALL develops from early formation of T-cells, which also play an important role in the body's natural defenses.

Princeton University is ranked the third best university in the nation by  College Consensus, a college ratings website that aggregates publisher rankings and student reviews.  College Consensus combined the latest results from college rankings with thousands of real student reviews to produce a consensus score for each school. In the category of Best Colleges in New Jersey, Princeton University earned the top spot and was followed by The College of New Jersey, Rutgers University-New Brunswick, the Stevens Institute of Technology, Stockton University, Rutgers University-Camden, Drew University, Monmouth University, Rider University, Ramapo College of New Jersey, Rutgers University-Newark, Saint Peter's University, Seton Hall University, Caldwell University, Fairleigh Dickinson University Metropolitan Campus, the New Jersey Institute of Technology, Kean University, William Paterson University, Montclair State University, Centenary University, Rowan University and Georgian Court University.

New Jersey Institute of Technology  is creating a center that will conduct basic and applied research focusing on interdisciplinary research and development for all areas pertaining to digital data. The Institute of Data Science, unveiled July 9, will be led by David Bader, a distinguished professor at NJIT. At the institute, scientists, engineers and users will develop technologies applicable in the "real world," NJIT said, working beyond academic research to solve "problems in the modern data-driven economy."

The  Hackensack Meridian School of Medicine at  Seton Hall University announced it welcomed its second class of 91 students. The students were selected out of nearly 5,000 applications, Hackensack said.  "Dynamic changes in health care require a new approach to medical education and we are thrilled to welcome our next class of future physicians who will humanize health care," said  Robert C. Garrett , CEO of  Hackensack Meridian Health .

Special Programs from Our Partners for BioNJ Members

The New Jersey Innovation Institute provides Strategic Doing 301, a 2.5-day training in the deep skills, tools and frameworks of agile strategy and collaboration. Called Strategic Doing, this discipline teaches participants how to design and guide complex collaborations by following simple rules. The training is ideally suited to anyone interested in developing the skills to lead complex collaborations and to innovate in open, loosely connected networks. The course has inspired hundreds of collaborative initiatives for communities, regions, businesses, health systems, government agencies and universities.

This year's Governor's Conference on Housing and Economic Development will gather industry experts and decision makers in business and government, housing and economic development, and the nonprofit community from throughout the State for two days of informed discussion, empowering ideas and engaging trade and industry exhibitors.

September 18, 2019 l New Brunswick
The  U.S. Small Business Administration  is hitting the road and Middlesex County's own New Brunswick has been announced as a stop on the 16 spot tour. The SBA's excursion aims to connect entrepreneurs to its Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) programs, according to the organization the largest source of early stage funding in the country. The SIBR Road Tour will arrive in New Brunswick on Sept. 18 to be hosted by an as yet unnamed local organization. The SBA said host groups will be involved in next-generation research and development and supporting entrepreneurs.

October 2, 2019 l Princeton University
Princeton's Science and Technology Job Fair is ideal for finding exceptionally talented individuals to staff critical projects, as well as bringing in the best prospects for summer internships. Last year, over 1,000 undergraduate and graduate students attended.  Please visit Princeton's website  for further details and the link to online registration. Space is limited and is allocated on a first-come, first-served basis.  Please contact Traci Miller at [email protected] with any questions.

October 11, 2019 l Rutgers University - Busch Campus, Piscataway
Explore the extensive research capabilities available in New Jersey to researchers in industry and academia. 

November 14, 2019 | Princeton

Save the date! Annual evening reception highlighting the innovative research  emerging from our labs and working spaces and the translation of that research through entrepreneurship, technology transfer and engagement with industry. We invite you to join us as we strengthen connections, exchange ideas and build our innovation ecosystem among our external partners and our world-renowned faculty, research teams, students and alumni. The reception will be held at the Frick Chemistry Laboratory, Princeton University, Princeton NJ 08544. See technologies from previous events at Celebrate Princeton Innovation.

The NJBAC is a state agency offering free and confidential assistance to help your business grow. As a "one-stop shop," NJBAC can help businesses of all sizes and types to manage the state's regulatory processes, boost exports, gain access to financial resources where applicable and tackle other obstacles along the way. You can download the NJBAC guide by clicking here or contact their business advocates at 1-800 JERSEY 7. 

Please contact BioNJ at [email protected] or call 609-890-3185 
with any questions.